Exicure Inc (XCUR) - Total Assets
Based on the latest financial reports, Exicure Inc (XCUR) holds total assets worth $12.76 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Exicure Inc (XCUR) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
Exicure Inc - Total Assets Trend (2015–2025)
This chart illustrates how Exicure Inc's total assets have evolved over time, based on quarterly financial data. See Exicure Inc (XCUR) net assets for net asset value and shareholders' equity analysis.
Exicure Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Exicure Inc's total assets of $12.76 Million consist of 32.9% current assets and 67.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 26.7% |
| Accounts Receivable | $58.00K | 0.4% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $3.78 Million | 27.0% |
| Goodwill | $4.40 Million | 31.3% |
Asset Composition Trend (2015–2025)
This chart illustrates how Exicure Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Exicure Inc.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Exicure Inc's current assets represent 32.9% of total assets in 2025, a decrease from 97.9% in 2015.
- Cash Position: Cash and equivalents constituted 26.7% of total assets in 2025, down from 95.5% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 57.0% of total assets, an increase from 0.0% in 2015.
- Asset Diversification: The largest asset category is goodwill at 31.3% of total assets.
Exicure Inc Competitors by Total Assets
Key competitors of Exicure Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
ALTEOGEN Inc
KQ:196170
|
Korea | ₩729.47 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $440.10 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Galapagos N.V.
AS:GLPG
|
Netherlands | €3.37 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
Exicure Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.79 | 2.91 | 4.76 |
| Quick Ratio | 0.79 | 2.91 | 4.47 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-928.00K | $7.42 Million | $47.90 Million |
Exicure Inc - Advanced Valuation Insights
This section examines the relationship between Exicure Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.80 |
| Latest Market Cap to Assets Ratio | 0.73 |
| Asset Growth Rate (YoY) | -6.7% |
| Total Assets | $14.04 Million |
| Market Capitalization | $10.20 Million USD |
Valuation Analysis
Below Book Valuation: The market values Exicure Inc's assets below their book value (0.73x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Exicure Inc's assets decreased by 6.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Exicure Inc (2015–2025)
The table below shows the annual total assets of Exicure Inc from 2015 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $14.04 Million | -6.74% |
| 2024-12-31 | $15.06 Million | +30.02% |
| 2023-12-31 | $11.58 Million | -50.36% |
| 2022-12-31 | $23.33 Million | -64.04% |
| 2021-12-31 | $64.87 Million | -35.42% |
| 2020-12-31 | $100.44 Million | -12.86% |
| 2019-12-31 | $115.26 Million | +300.83% |
| 2018-12-31 | $28.76 Million | -0.80% |
| 2017-12-31 | $28.99 Million | +40.88% |
| 2016-12-31 | $20.58 Million | +4.87% |
| 2015-12-31 | $19.62 Million | -- |
About Exicure Inc
Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. Exicure, Inc. was founded in 2011 and is headquartered in Redwood Ci… Read more